Testa D, Monza D, Ferrarini M, Soliveri P, Girotti F, Filippini G
Department of Neurology, C. Besta National Neurological Institute, Via Celoria 11, I-20133 Milan, Italy.
Neurol Sci. 2001 Jun;22(3):247-51. doi: 10.1007/s100720100021.
In order to identify early clinical features and survival predictors of supranuclear palsy (PSP) and multiple system atrophy (MSA), we compared the disease course of patients consecutively referred between 1987 and 1999 and followed to December 1999. Thirty-nine PSP and 74 MSA patients were diagnosed according to commonly accepted clinical criteria. Length of survival was ascertained from death certificates or by contacting relatives. Ten-year survival after disease onset was 29% for both disorders. Median survival was 7.0 years (PSP) and 7.5 (MSA). Neither age, symptoms at onset, or disability at diagnosis predicted survival. At diagnosis, all PSP patients had oculomotor palsy, whereas 89% of MSA patients had dysautonomia; bradykinesia and falls were the most frequent common signs. Distinctive early signs were palilalia, cognitive impairment and hyperreflexia in PSP; hypophonia, anterocollis and dysautonomia in MSA. MSA patients responded better to levodopa. Attention to early distinctive features can improve differential diagnosis and inform subsequent management.
为了确定核上性麻痹(PSP)和多系统萎缩(MSA)的早期临床特征及生存预测因素,我们比较了1987年至1999年间连续转诊并随访至1999年12月的患者的病程。根据公认的临床标准诊断出39例PSP患者和74例MSA患者。通过死亡证明或联系亲属确定生存时长。两种疾病发病后10年生存率均为29%。PSP的中位生存期为7.0年,MSA为7.5年。年龄、发病时症状或诊断时的残疾程度均不能预测生存情况。诊断时,所有PSP患者均有动眼神经麻痹,而89%的MSA患者有自主神经功能障碍;运动迟缓及跌倒为最常见的共同体征。PSP的特征性早期体征为言语重复、认知障碍和反射亢进;MSA为声音低微、颈前屈和自主神经功能障碍。MSA患者对左旋多巴反应更好。关注早期特征性表现可改善鉴别诊断并为后续治疗提供依据。